Results from the US Food and Drug Administration (FDA)-requested analyses at Week 16 showed that a significantly higher proportion of patients achieved HiSCR50 when treated with Cosentyx 300 mg ...

ZURICH, April 24 (Reuters) - Swiss drugmaker Novartis NOVN.S on Wednesday raised its 2019 guidance after a first-quarter earnings and sales beat, as revenue from its heart failure drug Entresto ...

The company noted that Cosentyx is backed by a wealth of research with 100 studies and has been proven to offer clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment ...